STOCK TITAN

iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Rhea-AI Summary
iCAD, Inc. highlights clinical evidence showing its AI solutions can reduce breast interval cancer rates and recall rates while lowering radiology reading workload. The company's ProFound Detection solution may serve as a biomarker for evaluating cardiovascular disease. New research presented at ECR 2024 demonstrates the efficacy of iCAD's AI in improving mammography screening efficiency and accuracy. The company also introduces enhancements to its ProFound Detection solution and showcases its Breast Health Suite at the event.
Positive
  • None.
Negative
  • None.

The integration of AI-powered tools like ProFound AI in breast cancer screening programs represents a significant advancement in oncology practice. From a clinical perspective, the reduction in workload for radiologists without compromising diagnostic accuracy is a noteworthy achievement. The 24.8% to 30.6% reduction in human reading workload, as indicated by the study, could allow radiologists to focus on more complex cases and potentially reduce burnout. Moreover, the modest improvement in recall rates suggests that the AI is refining the screening process, which could lead to earlier detection and treatment, ultimately improving patient outcomes.

Furthermore, the anticipated improvement in interval carcinoma detection rates is particularly promising. Interval carcinomas, which are cancers that appear between regular screening intervals, are often more aggressive and have a poorer prognosis. If AI can reliably reduce the incidence of these cancers by improving detection rates, it would be a significant step forward in breast health management. This would also align with the overarching goal of screening programs to catch cancers early when they are most treatable.

The retrospective evaluation of interval breast cancer using AI diagnostics is an area of interest that could reshape standard screening protocols. The expectation that ProFound AI could outperform traditional radiology in detecting interval carcinomas underlines the potential of AI in enhancing diagnostic accuracy. This could lead to a paradigm shift in how screenings are conducted, with AI-assisted readings becoming standard practice. However, it's important to scrutinize the sensitivity and specificity of the AI system in various populations, as these metrics are crucial for understanding the balance between detecting true positives and avoiding false positives.

Additionally, the use of AI-generated case scores to prioritize readings and expedite diagnosis for true positive cases is a strategic innovation. By focusing on higher-scoring cases, radiologists may be able to manage their workload more effectively while still adhering to regulatory timeframes for diagnosis. This approach could streamline the screening process, ensuring that patients with the highest risk are attended to promptly.

The detection of Breast Arterial Calcification (BAC) using ProFound AI Heart Health as a biomarker for cardiovascular disease is a fascinating development. BAC is typically an incidental finding during mammography, but its potential role as an indicator of atherosclerotic disease could be a game-changer for preventive health strategies in women. The reported correlation between a BAC score of 3 or more and a significantly higher rate of atherosclerotic disease indicates that mammography could serve a dual purpose in both cancer and cardiovascular disease screening.

This dual-screening approach could be particularly beneficial in identifying at-risk patients who may not have access to or seek out cardiovascular screening independently. However, the reported sensitivity, specificity and accuracy rates must be carefully considered when implementing such a screening protocol to ensure that it is both effective and efficient. The clinical implications of integrating BAC assessment into routine mammography could extend far beyond breast health, potentially leading to early interventions that could mitigate the risk of cardiovascular events.

  • Clinical evidence demonstrates ProFound Detection’s AI may help reduce breast interval cancer (IC) rates and decrease recall rates without additional false negatives
  • Findings reveal substantially lower radiology reading workload
  • Detection of Breast Arterial Calcification (BAC) by ProFound Heart Health could serve as biomarker to evaluate broader cardiovascular disease in women

NASHUA, N.H., Feb. 28, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes, will highlight scientific presentations, including an award-winning poster at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, Feb 28 – March 3, 2024. The Company also announced it will highlight a new release for its AI-powered ProFound Detection solution while showcasing its full Breast Health Suite in booth X1 AI-35.

“The data presented at ECR demonstrate the real-world ability to improve efficiency and accuracy in mammography breast screening—from reducing workloads without compromising accuracy to potentially reducing interval cancer rates and expediting diagnosis for true positive cases. These findings underscore ProFound AI’s transformative power to improve breast healthcare,” said Dana Brown, president and CEO of iCAD.

“Furthermore, we are thrilled to showcase new workstation features to improve the readability of iCAD’s primary solution, ProFound Detection,” continued Brown. “This includes limiting lesion marks to the three highest-scoring lesions, which may be color-coded based on lesion score. Additionally, the ProFound Scorecard may be color-coded based on case score categories, with options for score range fine-tuning based on a facility’s real-world data. For radiologists, these latest enhancements further improve and facilitate their reading of mammograms.”

New Research
The following three oral and award-winning poster presentations highlight the clinical research being presented at ECR 2024. Detailed information may be found here.

  • Friday, March 1, 8:00 – 9:00 am, RPS1202 – Adding Artificial Intelligence (AI) Case Malignancy Scoring in a Breast Screening Program to Reduce Screen-Reading Workload: A Retrospective Study. The study conducted by A. Nitrosi et al. at the Reggio Emilia Breast Screening Program in Italy aimed to assess the integration of iCAD’s artificial intelligence mammography case malignancy scoring (AI-CMS) into a breast screening program to alleviate screen-reading workload without compromising accuracy. Analyzing data from 31,747 screening exams, including 92 proven tumors, the study simulated two integrated AI and human reading protocols (ProFound AI 2D system). Results showed that implementing ProFound AI-CMS could substantially reduce the number of human readings and workload by 24.8% to 30.6%, with a modest improvement in recall rate and no increase in false negatives observed with 10% and 15% Case Score thresholds.

  • Sunday, March 3, 9:30 – 11:00 am, RPS2305 – Retrospective Evaluation of Interval Breast Cancer: Can the Number of Interval Carcinomas be Reduced Utilizing AI Diagnostic Software? In this study conducted by Jonas Subelack et al., researchers from the University of St. Gallen and Krebsliga Ostschweiz in Switzerland and Radiologie am Theater in Germany assessed whether iCAD’s ProFound AI could help reduce interval carcinomas (ICs). Analyzing data from 151,245 screening mammograms between 2010 and 2019, the study identified 264 ICs where cancer was detected within 24 months after screening that was considered normal. Expected results anticipate improved IC detection rates with the software compared to initial screening, with detection accuracy influenced by set thresholds. The study expects the software to outperform radiologists in IC detection, suggesting potential integration into mammography screening to reduce ICs.

  • Sunday, March 3, 11:30 am – 12:30 pm - RPS 2405 – Adding Artificial Intelligence (AI) Case Malignancy Scoring in a Breast Screening Program to Overcome Delay in Most Probably True Positive Cases: A Retrospective Study. The retrospective study at the Reggio Emilia Breast Screening Program in Italy led by A. Nitrosi et al. aimed to assess the efficacy of implementing iCAD’s ProFound AI case scoring strategy in a breast screening program to expedite the reading process for potentially true positive cases, ensuring compliance with local regulations requiring readings within two weeks. Analyzing data from 32,012 2D mammography screening exams, the study utilized the ProFound AI 2D system. The AI-generated Case Scores, representing the algorithm's confidence in malignancy, were used to prioritize readings. Results showed that reading screening exams above certain Case Score thresholds identified 61% to 89% of screen-detected cancers while requiring only 5.4% to 20% of screening exams to be read. Notably, prioritizing readings of exams with Case Scores above 40% allowed for the recall of the majority (85%) of true positive cases within a short time frame.

  • ECR 2024 Awarded - Certificate of Merit
    E-Poster Presentation – Breast Arterial Calcification (BAC): A Proxy for Medium and Large Vessel Atherosclerotic Calcium. In this retrospective study by C. Parghi et al., researchers investigated the correlation between breast arterial calcification (BAC) as detected by ProFound AI Heart Health on screening mammograms from Solis Mammography and the extent of atherosclerotic disease observed on CT imaging within 12 months of the mammogram. Analyzing data from 1,449 women, they found that a BAC score of 3 or more was associated with a significantly higher rate of clinically significant atherosclerotic disease in large and medium vessels compared to a BAC score of less than 3. Specifically, the rate increased from 11.0% to 31.0% (p < 0.001). The sensitivity, specificity, and accuracy for detecting clinically significant atherosclerotic disease when the BAC score was 3 or more were 21.8%, 92.9%, and 83.8% respectively. These findings suggest that quantitative BAC assessment could offer insight and potentially identify those who need further cardiovascular screening.

Chirag Parghi, M.D., chief medical officer of Solis Mammography and a pioneer in the use of mammography to assess BAC, won the Certificate of Merit award for this poster presentation. “I am encouraged by our findings, which highlight the potential of Breast Arterial Calcification (BAC) assessment in revolutionizing access to cardiovascular risk assessment. Our research demonstrates the significance of a quantitative BAC score indicating a higher likelihood of clinically significant atherosclerotic disease elsewhere in the body, identifying individuals who may benefit from further cardiovascular screening. These results continue to advocate for screening mammography as a portal to screen for both breast cancer and cardiovascular risk, the top two causes of death in women worldwide."

Enhancements for ProFound Detection for 2D and 3D Mammography
The new workstation features included in the updates to ProFound Detection’s Third Generation solution were designed to improve readability of iCAD results through a configuration option to limit to three lesion marks visible on a 3D view. This refinement ensures that radiologists can interpret the most critical information without multiple markings, streamlining the diagnostic process for more efficient decision-making.

Moreover, the introduction of color-coded lesion marks and case score on the ProFound Scorecard provides an intuitive visual aid, allowing radiologists to discern the suspicion level of detected abnormalities quickly. This color-coded system, based on cancer occurrence per screening population, offers a concise, comprehensive representation of the severity of detected lesions and the overall case, further facilitating accurate diagnosis and prioritization of cases.

Additionally, support for the ability to fine-tune score ranges based on real-world data enables users to customize the detection system according to their specific clinical needs, supporting performance and adaptability to varying patient populations.

Lastly, iCAD will highlight expanded cloud platform and subscription licensing plans marking a significant advancement in deployment flexibility. iCAD’s new Success Program offers a full range of ongoing software updates to ensure customers have the latest version of iCAD’s AI offerings, system maintenance, and customer support.

To discover more about iCAD’s presence at the ECR 2024 annual meeting or to schedule time with the iCAD team, virtually or in-person, visit www.icadmed.com/ecr-2024

About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly 30% being tomosynthesis. For more information, including the latest in regulatory clearances, please visit www.icadmed.com.

Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

CONTACTS

Media inquiries: pr@icadmed.com
Investor Inquiries: ir@icadmed.com


FAQ

How can iCAD's AI solutions help reduce breast interval cancer rates and recall rates?

iCAD's AI solutions have shown in clinical evidence to potentially reduce breast interval cancer rates and recall rates while decreasing radiology reading workload.

What is the significance of detecting Breast Arterial Calcification (BAC) using ProFound Heart Health?

Detecting BAC using ProFound Heart Health could serve as a biomarker for evaluating broader cardiovascular disease in women.

What were the key findings from the research presented at ECR 2024 regarding iCAD's AI solutions?

The research highlighted at ECR 2024 demonstrated the ability of iCAD's AI solutions to improve efficiency and accuracy in mammography screening, potentially reducing interval cancer rates and expediting diagnosis for true positive cases.

What enhancements were introduced for ProFound Detection for 2D and 3D mammography?

Enhancements for ProFound Detection include features such as limiting lesion marks to three on a 3D view, introducing color-coded lesion marks and case scores, and support for fine-tuning score ranges based on real-world data.

What does iCAD's new Success Program offer?

iCAD's new Success Program provides ongoing software updates, system maintenance, and customer support to ensure customers have the latest version of iCAD's AI offerings.

iCAD, Inc.

NASDAQ:ICAD

ICAD Rankings

ICAD Latest News

ICAD Stock Data

46.14M
24.81M
5.82%
28.53%
1.71%
Small Arms, Ordnance, and Ordnance Accessories Manufacturing
Manufacturing
Link
United States of America
NASHUA

About ICAD

icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.